Tissue Transglutaminase (tTG; expressed in Baculovirus/Sf9)

Cat. No.	Available in
15200	0.1 mg
15201	1.0 mg

Data Sheet (english)
Data Sheet (french)
Data Sheet (chinese)

Specification Sheet
MSDS

Celiac disease is an enteropathy that is characterized by intestinal lesions of variable severity. Tissue-type transglutaminase (tTG) is believed to be the predominant autoantigen for celiac disease, and the corresponding autoantibodies show higher sensitivity and specificity than anti-gliadin antibodies. Highly pure recombinant human tTG is continuously replacing the traditionally used tTG fraction from guinea pig.

Tissue-type transglutaminase antigens from DIARECT have been specifically modified for improved handling: exchange of an active site amino acid eliminates the protein cross-linking activity of the enzyme, while maintaining the native three-dimensional structure and the enzyme's secondary GTPase activity. This engineering assures reproducible properties of the antigen preparations by eliminating variable and ill-defined covalent aggregates of tTG antigen and host-cell proteins.

Two recombinant human tissue transglutaminase products are available from DIARECT, produced in baculovirus / insect cell expression system and E. coli, respectively (follow this link for the page of the E. coli-expressed tTG antigen).